Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus()

Hepatitis B virus (HBV) targets the liver and is a major driver for liver cancer. Clinical data suggest that HBV infection is associated with reduced response to treatment with the multi-kinase inhibitor sorafenib, the first available molecularly targeted anti-hepatocellular carcinoma (HCC) drug. Gi...

Descripción completa

Detalles Bibliográficos
Autores principales: Witt-Kehati, Dvora, Fridkin, Alexandra, Alaluf, Maya Bitton, Zemel, Romy, Shlomai, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884218/
https://www.ncbi.nlm.nih.gov/pubmed/29524828
http://dx.doi.org/10.1016/j.tranon.2018.02.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884218/
https://www.ncbi.nlm.nih.gov/pubmed/29524828
http://dx.doi.org/10.1016/j.tranon.2018.02.015

Ejemplares similares